NO20093217L - Makrocykliske analoger og fremgangsmater for fremstilling og anvendelse derav - Google Patents

Makrocykliske analoger og fremgangsmater for fremstilling og anvendelse derav

Info

Publication number: NO20093217L
Authority: NO; Norway
Prior art keywords: preparation; processes; macrocyclic analogues; macrocyclic; analogues
Prior art date: 1998-06-17

Application number

NO20093217A

Other languages

English (en)

Other versions

NO331183B1 (no

Inventor

Monica Palme

Wanjun Zheng

Bruce A Littlefield

Boris M Seletsky

Murray J Towle

Melvin J Yu

Original Assignee

Eisai R&D Man Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-06-17

Filing date

2009-10-26

Publication date

2001-02-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22219026&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20093217(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-02-15 Publication of NO20093217L publication Critical patent/NO20093217L/no

2009-10-26 Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd

2011-10-24 Publication of NO331183B1 publication Critical patent/NO331183B1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Medicinal Preparation (AREA)
Steroid Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Saccharide Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Peptides Or Proteins (AREA)

NO20093217A 1998-06-17 2009-10-26 Farmasoytisk preparat omfattende en halokondrinanalog eller et farmasoytisk salt derav og en farmasoytisk akseptabel baerer NO331183B1 (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US8968298P	1998-06-17	1998-06-17

Publications (2)

Publication Number	Publication Date
NO20093217L true NO20093217L (no)	2001-02-15
NO331183B1 NO331183B1 (no)	2011-10-24

Family

ID=22219026

Family Applications (5)

Application Number	Title	Priority Date	Filing Date
NO20006316A NO328280B1 (no)	1998-06-17	2000-12-12	Makrocykliske analoger
NO20093217A NO331183B1 (no)	1998-06-17	2009-10-26	Farmasoytisk preparat omfattende en halokondrinanalog eller et farmasoytisk salt derav og en farmasoytisk akseptabel baerer
NO2011018C NO2011018I1 (no)	1998-06-17	2011-09-16	Eribulin og farmasøytisk akseptable salter derav
NO2011026C NO2011026I2 (no)	1998-06-17	2011-12-14	Eribulin eller et farmasøytisk akseptabelt salt derav
NO2022019C NO2022019I1 (no)	1998-06-17	2022-06-03	Eribulin eller et farmasøytisk akseptabelt salt derav - forlenget SPC

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
NO20006316A NO328280B1 (no)	1998-06-17	2000-12-12	Makrocykliske analoger

Family Applications After (3)

Application Number	Title	Priority Date	Filing Date
NO2011018C NO2011018I1 (no)	1998-06-17	2011-09-16	Eribulin og farmasøytisk akseptable salter derav
NO2011026C NO2011026I2 (no)	1998-06-17	2011-12-14	Eribulin eller et farmasøytisk akseptabelt salt derav
NO2022019C NO2022019I1 (no)	1998-06-17	2022-06-03	Eribulin eller et farmasøytisk akseptabelt salt derav - forlenget SPC

Country Status (23)

Country	Link
US (4)	US6214865B1 (no)
EP (4)	EP2272839B1 (no)
JP (1)	JP4454151B2 (no)
KR (1)	KR100798600B1 (no)
CN (1)	CN1216051C (no)
AT (1)	ATE502932T1 (no)
AU (1)	AU762998B2 (no)
BE (1)	BE2011C028I2 (no)
BR (1)	BRPI9911326B8 (no)
CA (3)	CA2335300C (no)
CY (2)	CY1111516T1 (no)
DE (2)	DE122011100031I1 (no)
DK (1)	DK1087960T3 (no)
FR (1)	FR11C0038I2 (no)
HK (1)	HK1035534A1 (no)
HU (1)	HU227912B1 (no)
IL (1)	IL139960A0 (no)
LU (1)	LU91854I2 (no)
NO (5)	NO328280B1 (no)
NZ (1)	NZ508597A (no)
PT (1)	PT1087960E (no)
WO (1)	WO1999065894A1 (no)
ZA (1)	ZA200007159B (no)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1999065894A1 (en) *	1998-06-17	1999-12-23	Eisai Co., Ltd.	Macrocyclic analogs and methods of their use and preparation
US8097648B2 (en) *	1998-06-17	2012-01-17	Eisai R&D Management Co., Ltd.	Methods and compositions for use in treating cancer
US6653341B1 (en) *	1998-06-17	2003-11-25	Eisai Co., Ltd.	Methods and compositions for use in treating cancer
DE10037310A1 (de) *	2000-07-28	2002-02-07	Asta Medica Ag	Neue Indolderivate und deren Verwendung als Arzneimittel
EP1531846A4 (en) *	2002-02-27	2006-04-19	Us Gov Health & Human Serv	Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
NZ535139A (en)	2002-03-22	2007-07-27	Eisai Co Ltd	Hemiasterlin derivatives and uses thereof in the treatment of cancer
US20050075395A1 (en) *	2003-05-28	2005-04-07	Gary Gordon	Continuous dosing regimen
WO2004105794A2 (en) *	2003-05-29	2004-12-09	Abbott Laboratories	Continuous dosing regimen with abt-751
US20070196418A1 (en) *	2003-07-29	2007-08-23	Michael Lewis	Drug delivery methods and devices
CN1993342A (zh) *	2004-06-03	2007-07-04	卫材株式会社	用于制备软海绵素b的中间体
CA2567984C (en)	2004-06-03	2014-05-20	Eisai Co., Ltd.	Intermediates for the preparation of analogs of halichondrin b
US20060045846A1 (en) *	2004-08-30	2006-03-02	Horstmann Thomas E	Reagents and methods for labeling terminal olefins
EP1831697A4 (en) *	2004-12-09	2011-01-26	Eisai R&D Man Co Ltd	SCREENING OF TUBULIN ISOTYPE IN CANCER THERAPY USING ANALOGUES OF HALICHONDRIN B
EP2200992B1 (en)	2007-10-03	2014-02-26	Eisai R&D Management Co., Ltd.	Intermediates and methods for the synthesis of halichondrin b analogs
SG189739A1 (en) *	2008-04-04	2013-05-31	Eisai R&D Man Co Ltd	Halichondrin b analogs
RU2476216C1 (ru) *	2009-03-30	2013-02-27	Эйсай Ар Энд Ди Менеджмент Ко., Лтд.	Липосомальная композиция
MY160203A (en)	2009-03-30	2017-02-28	Eisai R&D Man Co Ltd	Liposome composition
EP2415464B1 (en)	2009-03-30	2017-05-10	Eisai R&D Management Co., Ltd.	Method for producing liposome composition
JP5556811B2 (ja) *	2009-04-14	2014-07-23	日産化学工業株式会社	テトラヒドロピラン化合物の製造方法
SG10201500552PA (en)	2010-01-26	2015-03-30	Eisai R&D Man Co Ltd	Furo [3, 2 -b] pyrane derivatives useful in the synthesis of halichondrin b analogs
SG193489A1 (en)	2011-03-18	2013-10-30	Eisai R&D Man Co Ltd	Methods and compositions for predicting response to eribulin
WO2012147900A1 (en)	2011-04-28	2012-11-01	Eisai R&D Management Co., Ltd.	Microreactor process for halichondrin b analog synthesis
EP3444363B1 (en)	2011-06-03	2020-11-25	Eisai R&D Management Co., Ltd.	Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
CN104053645A (zh)	2011-11-30	2014-09-17	阿方拉研究股份有限公司	用于制备(3r)-2,4-二-离去基团-3-甲基丁-1-烯的工艺
US9174956B2 (en)	2011-12-16	2015-11-03	Alphora Research Inc.	Process for preparation of 3-((2S,5S)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl)propanol derivatives and intermediates useful thereof
CN104080793B (zh) *	2011-12-29	2017-09-19	阿方拉研究股份有限公司	2‑((2s,3s,4r,5r)‑5‑((s)‑3‑氨基‑2‑羟基丙‑1‑基)‑4‑甲氧基‑3‑(苯磺酰甲基)四氢呋喃‑2‑基)乙醛衍生物以及它们的制备方法
WO2013142999A1 (en) *	2012-03-30	2013-10-03	Alphora Research Inc.	Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein
WO2014087230A1 (en)	2012-12-04	2014-06-12	Eisai R&D Management Co., Ltd.	Use of eribulin in the treatment of breast cancer
AR096238A1 (es)	2013-05-15	2015-12-16	Alphora Res Inc	Proceso para preparar derivados de 3-((2s,5s)-4-metilen-5-(3-oxopropil)tetrahidrofuran-2-il)propanol e intermediarios útiles para el mismo
CA2915005C (en)	2013-06-26	2021-12-28	Eisai R&D Management Co., Ltd.	Use of eribulin and lenvatinib as combination therapy for treatment of cancer
CA2916537C (en) *	2013-07-03	2021-07-27	Alphora Research Inc.	Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein including intermediates containing -so2-(p-tolyl) groups
CN103483352A (zh) *	2013-10-18	2014-01-01	李友香	抗肿瘤的药用原料药
CN114716453A (zh)	2013-11-04	2022-07-08	卫材R&D管理有限公司	软海绵素b的类似物合成中有用的大环化反应和中间体
RU2676486C1 (ru)	2013-12-06	2018-12-29	Эйсай Ар Энд Ди Менеджмент Ко., Лтд.	Способы, предназначенные для синтеза аналогов галихондрина b
CN104860978A (zh) *	2014-02-20	2015-08-26	正大天晴药业集团股份有限公司	软海绵素b类似物的合成中间体
TW201617326A (zh) *	2014-03-06	2016-05-16	Ａｌｐｈｏｒａ研發股份有限公司	（ｓ）－１－（（２ｒ，３ｒ，４ｓ，５ｓ）－５－烯丙－３－甲氧－４－（對甲苯磺醯甲基）四氫呋喃－２－基）－３－氨基丙－２－醇之結晶衍生物
US20170100367A1 (en)	2014-05-28	2017-04-13	Eisai R&D Management Co., Ltd.	Use of eribulin in the treatment of cancer
JP2017520586A (ja)	2014-06-30	2017-07-27	プレジデントアンドフェローズオブハーバードカレッジ	ハリコンドリン類似体の合成およびその使用
RS63559B1 (sr)	2014-08-28	2022-10-31	Eisai R&D Man Co Ltd	Derivat hinolina velike čistoće i postupak za njegovu proizvodnju
US10208058B2 (en)	2014-09-09	2019-02-19	Cipla Limited	Process for the preparation of macrocyclic ketone analogs of halichondrin B or pharmaceutically acceptable salts and intermediates thereof
CN105713031B (zh) *	2014-12-05	2021-05-07	正大天晴药业集团股份有限公司	一种用于制备艾日布林的中间体及其制备方法
SG11201706630UA (en)	2015-02-25	2017-09-28	Eisai R&D Man Co Ltd	Method for suppressing bitterness of quinoline derivative
CN107810013B (zh)	2015-03-04	2021-04-02	默沙东公司	用于治疗癌症的pd-1拮抗剂和艾立布林的组合
AU2015384801B2 (en)	2015-03-04	2022-01-06	Eisai R&D Management Co., Ltd.	Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
US10344038B2 (en)	2015-04-30	2019-07-09	President And Fellows Of Harvard College	Chromium-mediated coupling and application to the synthesis of halichondrins
CN107849057B (zh)	2015-05-07	2020-11-10	卫材R&D管理有限公司	用于合成软海绵素大环内酯的大环化反应及中间体和其他片段
WO2016182850A1 (en)	2015-05-08	2016-11-17	Albany Molecular Research, Inc.	Methods and intermediates for the preparation of omacetaxine and cephalotaxine derivatives thereof
CA2988707C (en)	2015-06-16	2023-10-10	Eisai R&D Management Co., Ltd.	Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
RU2718048C2 (ru)	2015-08-20	2020-03-30	Эйсай Ар Энд Ди Менеджмент Ко., Лтд.	Противоопухолевое терапевтическое средство
SG11201806133UA (en)	2016-02-12	2018-08-30	Eisai R&D Man Co Ltd	Intermediates in the synthesis of eribulin and related methods of synthesis
EP3449921B1 (en)	2016-04-28	2023-05-31	Eisai R&D Management Co., Ltd.	Eribulin for inhibiting tumor growth
CN109415383A (zh) *	2016-05-26	2019-03-01	雷迪博士实验室有限公司	制备艾日布林的方法及其中间体
SG11201811671XA (en)	2016-06-30	2019-01-30	Eisai R&D Man Co Ltd	Prins reaction and intermediates useful in the synthesis of halichondrin macrolides and analogs thereof
KR20190082782A (ko)	2016-10-14	2019-07-10	머크 샤프 앤드 돔 코포레이션	요로상피암을 치료하기 위한 pd-1 길항제 및 에리불린의 조합
JP6978758B2 (ja)	2016-11-11	2021-12-08	プレジデントアンドフェローズオブハーバードカレッジ	パラジウム媒介ケトール化
US10836776B2 (en)	2016-11-23	2020-11-17	Dr. Reddy's Laboratories Limited	Process for preparation of eribulin and intermediates thereof
KR101991710B1 (ko)	2017-12-14	2019-06-21	연성정밀화학(주)	에리불린 메실산염의 제조 중간체 및 그의 제조방법
KR101880939B1 (ko)	2017-01-02	2018-08-17	연성정밀화학(주)	에리불린 메실산염의 제조 중간체 및 그의 제조방법
US10865212B2 (en)	2017-01-02	2020-12-15	Yonsung Fine Chemical Co.. Ltd.	Intermediate for preparing eribulin mesylate and process for preparing the same
CN108341738B (zh) *	2017-01-24	2022-10-21	江苏恒瑞医药股份有限公司	用于制备艾日布林的方法及其中间体
CN108341828B (zh) *	2017-01-24	2021-04-06	江苏恒瑞医药股份有限公司	用于制备艾日布林的方法及其中间体
KR20240023674A (ko)	2017-04-05	2024-02-22	프레지던트 앤드 펠로우즈 오브 하바드 칼리지	마크로시클릭 화합물 및 그의 용도
US9938288B1 (en)	2017-04-05	2018-04-10	President And Fellows Of Harvard College	Macrocyclic compound and uses thereof
US11498892B2 (en)	2017-07-06	2022-11-15	President And Fellows Of Harvard College	Fe/Cu-mediated ketone synthesis
BR112020000141A2 (pt)	2017-07-06	2020-07-14	President And Fellows Of Harvard College	síntese de halicondrinas
US20190046513A1 (en)	2017-08-10	2019-02-14	Huya Bioscience International, Llc	Combination therapies of hdac inhibitors and tubulin inhibitors
CN109694379B (zh) *	2017-10-24	2020-09-11	江苏恒瑞医药股份有限公司	用于制备艾日布林的中间体及其制备方法
KR102177992B1 (ko) *	2017-11-09	2020-11-12	연성정밀화학(주)	에리불린 메실산염의 제조 중간체 및 그의 제조방법
WO2019099646A1 (en)	2017-11-15	2019-05-23	President And Fellows Of Harvard College	Macrocyclic compounds and uses thereof
EP3713565A1 (en)	2017-11-20	2020-09-30	Basilea Pharmaceutica International AG	Pharmaceutical combinations for use in the treatment of neoplastic diseases
WO2019102490A1 (en)	2017-11-21	2019-05-31	Natco Pharma Limited	Intermediates for the preparation of eribulin thereof
WO2019136145A1 (en)	2018-01-03	2019-07-11	Eisai R&D Management Co., Ltd.	Prins reaction and compounds useful in the synthesis of halichondrin macrolides and analogs thereof
WO2019211877A1 (en)	2018-05-03	2019-11-07	Cipla Limited	Process for the preparation of macrocyclic ketone analogs of halichondrin b
WO2020008382A1 (en) *	2018-07-04	2020-01-09	Dr. Reddy’S Laboratories Limited	Process for preparation of eribulin and intermediates thereof
EP3823973A4 (en) *	2018-07-20	2022-09-21	Dr. Reddy's Laboratories Limited	PURIFICATION PROCESSES FOR THE MANUFACTURE OF ERIBULIN AND INTERMEDIATE PRODUCTS THEREOF
WO2020075027A1 (en) *	2018-10-09	2020-04-16	Dr. Reddy's Laboratories Limited	Process for preparation of eribulin and intermediates thereof
US11447499B2 (en)	2019-06-14	2022-09-20	Rk Pharma Inc.	Process for the preparation of eribulin mesylate intermediate
WO2020255164A1 (en)	2019-06-21	2020-12-24	Council Of Scientific And Industrial Research	A chemo-enzymatic process for the preparation of homopropargylic alcohol
US12036204B2 (en)	2019-07-26	2024-07-16	Eisai R&D Management Co., Ltd.	Pharmaceutical composition for treating tumor
US11083705B2 (en)	2019-07-26	2021-08-10	Eisai R&D Management Co., Ltd.	Pharmaceutical composition for treating tumor
JOP20220070A1 (ar)	2019-11-07	2023-01-30	Eisai Randd Man Co Ltd	مترافقات جسم مضاد- عقار مضاد لميزوثيلين إيريبولين وطرق استخدامها
CN113135876B (zh) *	2020-01-16	2024-05-17	南通诺泰生物医药技术有限公司	艾日布林及其中间体的制备方法
KR20220130160A (ko) *	2020-01-22	2022-09-26	상하이 센후이 메디슨 컴퍼니 리미티드	에리불린 유도체의 약물 접합체, 이를 제조하기 위한 방법 및 의료분야에서 이의 용도
KR102377262B1 (ko)	2020-05-11	2022-03-22	연성정밀화학(주)	결정성 에리불린 염
IL279168B (en) *	2020-12-02	2022-04-01	Finetech Pharmaceutical Ltd	A process for the preparation of eribulin
CN113354659B (zh)	2021-06-08	2022-04-08	江苏慧聚药业股份有限公司	甲磺酸艾日布林的合成
MX2024000893A (es) *	2021-07-22	2024-02-06	Shanghai Senhui Medicine Co Ltd	Farmaco conjugado de un derivado de eribulina.
WO2023212746A2 (en) *	2022-04-30	2023-11-02	William Marsh Rice University	A unified strategy for the total syntheses of eribulin and a macrolactam analogue of halichondrin b
TW202434308A (zh) *	2023-01-17	2024-09-01	大陸商成都百利多特生物藥業有限責任公司	一種艾日布林類藥物的偶聯物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5338865A (en)	1992-03-12	1994-08-16	President And Fellows Of Harvard College	Synthesis of halichondrin B and norhalichondrin B
US5436238A (en)	1992-03-12	1995-07-25	President And Fellows Of Harvard College	Halichondrins and related compounds
GB9206244D0 (en)	1992-03-23	1992-05-06	Pharma Mar Sa	Cytotoxic compound from a marine sponge
US5426194A (en) *	1993-01-19	1995-06-20	Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University	Isolation and structure of Halistatin 1
US6653341B1 (en) *	1998-06-17	2003-11-25	Eisai Co., Ltd.	Methods and compositions for use in treating cancer
WO1999065894A1 (en) *	1998-06-17	1999-12-23	Eisai Co., Ltd.	Macrocyclic analogs and methods of their use and preparation
CA2567984C (en)	2004-06-03	2014-05-20	Eisai Co., Ltd.	Intermediates for the preparation of analogs of halichondrin b
EP2200992B1 (en)	2007-10-03	2014-02-26	Eisai R&D Management Co., Ltd.	Intermediates and methods for the synthesis of halichondrin b analogs
CN101910180A (zh)	2007-11-16	2010-12-08	卫材R&D管理有限公司	用于软海绵素b类似物合成的新颖中间体和用于该中间体的新颖脱磺酰化反应
SG189739A1 (en)	2008-04-04	2013-05-31	Eisai R&D Man Co Ltd	Halichondrin b analogs
SG10201500552PA (en)	2010-01-26	2015-03-30	Eisai R&D Man Co Ltd	Furo [3, 2 -b] pyrane derivatives useful in the synthesis of halichondrin b analogs

1999
- 1999-06-16 WO PCT/US1999/013677 patent/WO1999065894A1/en active IP Right Grant
- 1999-06-16 KR KR1020007014229A patent/KR100798600B1/ko active IP Right Review Request
- 1999-06-16 US US09/334,488 patent/US6214865B1/en not_active Expired - Lifetime
- 1999-06-16 CA CA002335300A patent/CA2335300C/en not_active Expired - Lifetime
- 1999-06-16 DE DE201112100031 patent/DE122011100031I1/de active Pending
- 1999-06-16 EP EP10010773A patent/EP2272839B1/en not_active Expired - Lifetime
- 1999-06-16 AU AU45739/99A patent/AU762998B2/en not_active Expired
- 1999-06-16 JP JP2000554719A patent/JP4454151B2/ja not_active Expired - Lifetime
- 1999-06-16 PT PT99928746T patent/PT1087960E/pt unknown
- 1999-06-16 DK DK99928746.9T patent/DK1087960T3/da active
- 1999-06-16 BR BRPI9911326A patent/BRPI9911326B8/pt not_active IP Right Cessation
- 1999-06-16 EP EP10010774A patent/EP2272840B1/en not_active Expired - Lifetime
- 1999-06-16 CN CN99809658XA patent/CN1216051C/zh not_active Expired - Lifetime
- 1999-06-16 CA CA2632433A patent/CA2632433C/en not_active Expired - Lifetime
- 1999-06-16 AT AT99928746T patent/ATE502932T1/de active
- 1999-06-16 EP EP10010772A patent/EP2277873B1/en not_active Expired - Lifetime
- 1999-06-16 CA CA2755266A patent/CA2755266C/en not_active Expired - Lifetime
- 1999-06-16 DE DE69943296T patent/DE69943296D1/de not_active Expired - Lifetime
- 1999-06-16 NZ NZ508597A patent/NZ508597A/en not_active IP Right Cessation
- 1999-06-16 EP EP99928746A patent/EP1087960B1/en not_active Expired - Lifetime
- 1999-06-16 IL IL13996099A patent/IL139960A0/xx active Protection Beyond IP Right Term
- 1999-06-16 HU HU0103357A patent/HU227912B1/hu active Protection Beyond IP Right Term
2000
- 2000-10-02 US US09/677,485 patent/US6365759B1/en not_active Expired - Lifetime
- 2000-12-04 ZA ZA200007159A patent/ZA200007159B/en unknown
- 2000-12-12 NO NO20006316A patent/NO328280B1/no not_active IP Right Cessation
2001
- 2001-04-26 US US09/843,617 patent/US6469182B1/en not_active Expired - Lifetime
- 2001-08-29 HK HK01106122.7A patent/HK1035534A1/xx not_active IP Right Cessation
2009
- 2009-10-26 NO NO20093217A patent/NO331183B1/no active Protection Beyond IP Right Term
2010
- 2010-08-12 US US12/855,412 patent/US8148554B2/en not_active Expired - Fee Related
2011
- 2011-06-01 CY CY20111100530T patent/CY1111516T1/el unknown
- 2011-08-12 CY CY2011010C patent/CY2011010I1/el unknown
- 2011-08-17 LU LU91854C patent/LU91854I2/fr unknown
- 2011-09-02 BE BE2011C028C patent/BE2011C028I2/fr unknown
- 2011-09-09 FR FR11C0038C patent/FR11C0038I2/fr active Active
- 2011-09-16 NO NO2011018C patent/NO2011018I1/no unknown
- 2011-12-14 NO NO2011026C patent/NO2011026I2/no unknown
2022
- 2022-06-03 NO NO2022019C patent/NO2022019I1/no unknown

Also Published As

Publication number	Publication date
CN1216051C (zh)	2005-08-24
CA2632433A1 (en)	1999-12-23
BR9911326A (pt)	2001-04-03
EP2277873A1 (en)	2011-01-26
US6214865B1 (en)	2001-04-10
DE122011100031I1 (de)	2011-12-15
NO2011018I1 (no)	2011-09-26
CA2335300C (en)	2008-10-07
US8148554B2 (en)	2012-04-03
HUP0103357A3 (en)	2002-10-28
US20110172446A1 (en)	2011-07-14
ZA200007159B (en)	2001-12-04
EP2277873B1 (en)	2012-05-30
KR20010083050A (ko)	2001-08-31
US6469182B1 (en)	2002-10-22
KR100798600B1 (ko)	2008-01-28
CA2755266C (en)	2014-08-12
JP4454151B2 (ja)	2010-04-21
HUP0103357A2 (hu)	2002-01-28
IL139960A0 (en)	2002-02-10
EP2272840B1 (en)	2012-08-22
EP1087960A1 (en)	2001-04-04
NO331183B1 (no)	2011-10-24
CN1312804A (zh)	2001-09-12
BE2011C028I2 (en)	2018-08-24
CY1111516T1 (el)	2014-04-09
DK1087960T3 (da)	2011-06-14
NO20006316D0 (no)	2000-12-12
BR9911326B1 (pt)	2015-01-06
PT1087960E (pt)	2011-06-17
BRPI9911326B8 (pt)	2021-05-25
HU227912B1 (en)	2012-05-29
HK1035534A1 (en)	2001-11-30
CA2755266A1 (en)	1999-12-23
CA2335300A1 (en)	1999-12-23
DE69943296D1 (de)	2011-05-05
NO328280B1 (no)	2010-01-25
EP2272840A1 (en)	2011-01-12
ATE502932T1 (de)	2011-04-15
EP2272839B1 (en)	2012-08-22
AU762998B2 (en)	2003-07-10
NO20006316L (no)	2001-02-15
AU4573999A (en)	2000-01-05
US6365759B1 (en)	2002-04-02
FR11C0038I1 (fr)	2011-10-14
LU91854I2 (fr)	2011-10-17
CY2011010I2 (el)	2014-04-09
NO2022019I1 (no)	2022-06-03
JP2002518384A (ja)	2002-06-25
EP1087960B1 (en)	2011-03-23
RU2245335C2 (ru)	2005-01-27
EP2272839A1 (en)	2011-01-12
NO2011026I2 (no)	2012-06-11
CY2011010I1 (el)	2014-04-09
CA2632433C (en)	2012-02-07
AU762998C (en)	2000-01-05
NO2011026I1 (no)	2012-01-09
NZ508597A (en)	2004-01-30
FR11C0038I2 (fr)	2013-01-11
EP1087960A4 (en)	2004-12-01
WO1999065894A1 (en)	1999-12-23

Publication	Publication Date	Title
NO20093217L (no)	2001-02-15	Makrocykliske analoger og fremgangsmater for fremstilling og anvendelse derav
DE69907977D1 (de)	2003-06-18	Pyrrolobenzodiazepine
DK0896533T3 (da)	2004-01-26	Pentafluorbenzensulfonamider og analoger
ATE267164T1 (de)	2004-06-15	9-(substituiertes glycyl)amido-6-(substituiert)-5-hydroxy-6-deoxy etracycline
HUP0000979A1 (hu)	2000-10-28	FK-506 jelű vegyületet és származékait tartalmazó gyógyászati készítmények
DK1414828T3 (da)	2008-02-04	Antitumoranaloger
NO20014925L (no)	2001-12-13	Farmasöytiske forbindelser
HK1045990A1 (en)	2002-12-20	Novel derivatives and analogues of galanthamin.
DK0736029T3 (da)	2006-05-15	Antikonvulsive pseudofructopyranosesulfamater
CY1106376T1 (el)	2011-10-12	Δικυκλικα παραγωγα των αμινο-πυραζινονων, μεθοδος παρασκευης τους και οι φαρμακευτικες συνθεσεις που τα πepιεχουν
BR0104358A (pt)	2002-01-02	Formulações de taxana tendo solubilidade aperfeiçoada
DK1073447T3 (da)	2007-09-03	N1-modificerede glycopeptider
FI952420A (fi)	1995-11-21	Glukopyranosidibentsotiofeenit
ATE330958T1 (de)	2006-07-15	Pyrazino 1'2':1,6öpyrido 3,4-böindolderivate
DK0520372T3 (da)	1997-05-12	Inositol-phosphat-analoger som calciumantagonistiske stoffer
FI901277A0 (fi)	1990-03-14	2,5,6,7-tetranor-4,8-inter-m-fenylen pg1z-derivativ.
ATE282608T1 (de)	2004-12-15	Chinoxalindionen
PT878195E (pt)	2002-09-30	Utilizacao de um composto 2-aroil-3-arilbenzo(b)tiofeno para a reducao de fibrinogenio
BR0214244A (pt)	2004-09-21	Uso de uma ascomicina
FI941850A0 (fi)	1994-04-21	Uusi yhdiste, joka on leustroduksiini H, sen valmistus ja terapeuttinen käyttö

Legal Events

Date	Code	Title	Description
2012-01-09	SPCF	Filing of supplementary protection certificate	Free format text: PRODUCT NAME: HALAVEN; NAT. REG. NO/DATE: EU/1/11/678/001-2 20110406; FIRST REG. NO/DATE: EU , EU/1/11/678/001-002 20110317 Spc suppl protection certif: 2011026 Filing date: 20111214
2012-06-11	SPCG	Granted supplementary protection certificate	Free format text: PRODUCT NAME: HALAVEN; NAT. REG. NO/DATE: EU/1/11/678/001-2 20110406; FIRST REG. NO/DATE: EU , EU/1/11/678/001-002 20110317 Spc suppl protection certif: 2011026 Filing date: 20111214 Extension date: 20240616
2019-07-08	MK1K	Patent expired
2022-06-13	SPCF	Filing of supplementary protection certificate	Free format text: PRODUCT NAME: ERIBULIN ELLER ET FARMASOEYTISK AKSEPTABELT SALT DERAV - FORLENGET SPC; NAT. REG. NO/DATE: EU/1/11/678/001-2 20110406; FIRST REG. NO/DATE: EU/1/11/678/001-002 20110317 Spc suppl protection certif: 2022019 Filing date: 20220603
2022-07-04	SPCF	Filing of supplementary protection certificate	Free format text: PRODUCT NAME: ERIBULIN ELLER ET FARMASOEYTISK AKSEPTABELT SALT DERAV - FORLENGET SPC; REG. NO/DATE: EU/1/11/678 20220603 Spc suppl protection certif: 2022025 Filing date: 20220613
2024-01-29	SPCG	Granted supplementary protection certificate	Free format text: PRODUCT NAME: ERIBULIN ELLER ET FARMASOEYTISK AKSEPTABELT SALT DERAV - FORLENGET SPC; NAT. REG. NO/DATE: EU/1/11/678/001-2 20110406; FIRST REG. NO/DATE: EU/1/11/678/001-002 20110317 Spc suppl protection certif: 2022019 Filing date: 20220603 Extension date: 20241216